Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720
| Autor: | Susanna Dunachie, Robert E. Sinden, Jenni M. Vuola, Angela Hunt-Cooke, Ian D. Poulton, Carolin Maier, Eveline L. Tierney, Tamara Berthoud, Sheila M. Keating, George B. Thornton, Filip Dubovsky, Daniel P. Webster, Geoffrey Butcher, Simon Correa, Adrian V. S. Hill, Sarah C. Gilbert, Rikke Fredslund Andersen, Michael Walther, Annette Schmidt, Laura Andrews, Pramod Sarpotdar, Jack Williams |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Hepatitis B virus Erythrocytes T cell Plasmodium falciparum Epitopes T-Lymphocyte parasitic diseases Malaria Vaccines medicine Animals Humans Amino Acid Sequence Malaria Falciparum B cell Reactogenicity General Veterinary General Immunology and Microbiology biology Malaria vaccine Immunogenicity Public Health Environmental and Occupational Health biology.organism_classification Virology Circumsporozoite protein Infectious Diseases medicine.anatomical_structure Sporozoites Immunology biology.protein Molecular Medicine Female Antibody |
| Zdroj: | Vaccine. 23(7) |
| ISSN: | 0264-410X |
| Popis: | ICC-1132, a recombinant virus-like particle comprising of a modified hepatitis B core protein with a B cell (NANP) and two T cell epitopes of Plasmodium falciparum circumsporozoite protein (CSP), was administered i.m. as a single 50 microg dose in Seppic ISA 720 to 11 volunteers. Local reactogenicity and systemic side effects were acceptable with the predominant finding being mild pain at the injection site. This regimen induced anti-NANP antibodies in 10/11 and modest T cell responses. There was no evidence of protection from experimental challenge with P. falciparum sporozoites. Other formulations and/or multi-dose regimens will be required to enhance the immunogenicity and efficacy of ICC-1132. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect